RYBREVANT® Access and Reimbursement Guide Overview
RYBREVANT® is indicated for specific NSCLC mutations, including EGFR exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 in…
High impact 84 min
Drug profile · INN
amivantamab-vmjw
RYBREVANT
amivantamab-vmjw (RYBREVANT) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — amivantamab-vmjw
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
amivantamab-vmjw (RYBREVANT) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN amivantamab-vmjw
Brand RYBREVANT
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Route INJECTION
Formulation INJECTABLE
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related research
Frequently asked questions
What is amivantamab-vmjw?
amivantamab-vmjw (RYBREVANT) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for amivantamab-vmjw?
RYBREVANT is a marketed brand name for amivantamab-vmjw. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amivantamab-vmjw?
amivantamab-vmjw has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.